Highlights
- Idiopathic pulmonary fibrosis (IPF) follows a predictable, conserved sequence of lung function decline that begins approximately a decade before clinical diagnosis.
- The diffusion capacity for carbon monoxide (DLCO) serves as a sentinel marker, declining steadily starting around 10 years before the disease reaches a threshold of 70%-predicted.
- Forced vital capacity (FVC) decline occurs much later and accelerates significantly as the disease progresses, with a 12-fold increase in the rate of decline between the early and late phases.
- Estimated years since onset (EYO) is a potent predictor of clinical outcomes, with every one-year increase in EYO associated with a 31% higher risk of death or lung transplant.
Background
Idiopathic pulmonary fibrosis (IPF) is a devastating, progressive interstitial lung disease characterized by the relentless accumulation of myofibroblasts and extracellular matrix, leading to the destruction of lung architecture and eventual respiratory failure. Historically, our understanding of the natural history of IPF has been limited by the fact that patients are typically diagnosed only after the onset of symptomatic breathlessness, by which time significant architectural distortion is already visible on high-resolution computed tomography (HRCT).
The “preclinical” phase of the disease—the period during which biological processes are active but clinical symptoms have not yet manifested—remains one of the most critical gaps in pulmonary medicine. Addressing this gap is essential for developing “interceptive” therapies that could potentially arrest the disease before irreversible fibrosis occurs. Until now, quantifying the speed and sequence of this progression has been hampered by the lack of longitudinal data spanning the pre-symptomatic to symptomatic transition. The study by Huang et al. (2026), published in the *American Journal of Respiratory and Critical Care Medicine*, provides a breakthrough by utilizing advanced Bayesian modeling to reconstruct this missing timeline.
Key Content
Methodological Innovation: The Disease Progression Model (DPM)
The researchers employed a Bayesian joint repeated measures model to synthesize data from two distinct populations: 245 adults with familial pulmonary fibrosis (FPF) and 347 patients with sporadic IPF from the placebo arms of randomized controlled trials (RCTs). FPF cohorts are uniquely valuable because family members of affected patients can be screened early, often identifying “subclinical” interstitial lung abnormalities (ILAs) before they meet the diagnostic criteria for IPF.
The central innovation of this study was the use of “Estimated Years since Onset” (EYO) as a temporal anchor. Because chronological age is a poor proxy for disease duration, the model used a latent variable to estimate when each subject reached a specific physiological milestone: a DLCO of 70%-predicted. By aligning patients based on this biological “Time Zero,” the researchers were able to map the trajectory of four pulmonary function test (PFT) parameters over a continuous multi-decade timeline.
The Sentinel Marker: DLCO Leads the Decline
The study reveals that the physiological signature of IPF begins far earlier than previously recognized. In the FPF cohort, DLCO began to decline steadily at approximately EYO -10 (ten years before the 70% threshold).
At EYO -5, the average DLCO was already significantly reduced at 86.8%-predicted, even though many of these individuals would still be considered “asymptomatic” or “subclinical” in a traditional clinical setting. By the time the disease reached EYO +5 (five years post-threshold), the DLCO plummeted to 45.3%-predicted. This suggests that gas exchange impairment, likely reflecting early alveolar epithelial cell dysfunction and microvascular loss, is the primary and earliest physiological manifestation of the fibrotic process.
The FVC Inflection Point: Late-Stage Acceleration
In contrast to DLCO, the Forced Vital Capacity (FVC)—which is the primary endpoint for almost all current IPF clinical trials—showed a markedly different trajectory. FVC remained relatively preserved in the early years, staying at 98.6%-predicted at EYO -5.
However, as the disease progressed, the rate of FVC loss accelerated exponentially. The annualized decline in FVC was only 0.49%-predicted at EYO -5 but increased to a staggering 6.14%-predicted at EYO +5. This 12-fold acceleration indicates that by the time FVC starts to drop significantly, the disease has already transitioned into a more aggressive, self-propagating phase.
Validation and Clinical Correlation
One of the most critical findings of the study was the consistency of this sequence across both FPF and sporadic IPF cohorts. Despite potential genetic differences (such as telomere mutations or MUC5B polymorphisms), the fundamental physiological pattern of DLCO leading and FVC following remained conserved.
Furthermore, the model’s temporal estimates (EYO) correlated strongly with clinical reality. Adjusting for age and sex, each one-year increase in EYO was associated with a 31% increased risk of the composite endpoint of death or lung transplant (Hazard Ratio 1.31, 95% CI 1.25-1.37). This validates EYO not just as a mathematical construct, but as a biologically relevant measure of disease burden.
Expert Commentary
The Biology of Sequential Decline
The physiological observation that DLCO decline precedes FVC decline by several years aligns with our evolving understanding of IPF pathogenesis. The earliest lesions in IPF are thought to occur at the bronchoalveolar junction. Early epithelial stress and the loss of alveolar type II cells impair the efficiency of gas exchange long before the bulk accumulation of collagen creates enough mechanical stiffness to significantly reduce the vital capacity. This study provides the clinical evidence for a “window of opportunity” where the lung is physiologically impaired but not yet structurally collapsed.
Implications for Early Screening and Intervention
Currently, guidelines do not recommend routine screening for IPF in the general population. However, for high-risk individuals (e.g., those with a strong family history or known genetic predispositions), these findings suggest that DLCO monitoring should be the cornerstone of surveillance. A stable FVC may provide a false sense of security, masking an underlying decade-long decline in gas exchange capacity.
Reshaping Clinical Trial Design
Perhaps the most profound impact of this research is on the design of future clinical trials. Most phase III trials require an FVC between 50% and 80% for enrollment. The DPM shows that these patients are already in the “accelerated decline” phase of their disease. If we are to test therapies aimed at preventing the initiation of fibrosis, we must recruit patients in the EYO -5 to EYO 0 range, where DLCO is falling but FVC is still preserved. This will require a shift toward using DLCO or composite physiological-imaging scores as primary endpoints in early-intervention trials.
Limitations
While the study is robust, it relies on the assumption that a DLCO of 70% represents a universal “onset” point. Additionally, because the data are synthesized from multiple sources, individual variability in the rate of progression (e.g., “slow progressors” vs. “rapid progressors”) still exists, although the conserved *sequence* seems to hold true across phenotypes.
Conclusion
The identification of a conserved, sequential decline in lung function in IPF—starting with a silent decade of DLCO loss followed by an accelerated FVC collapse—reframes our view of this disease from an acute clinical crisis to a chronic, multi-stage process. By providing a mathematical framework to estimate a patient’s position on this timeline, the Disease Progression Model (DPM) offers a powerful tool for clinicians to risk-stratify patients and for researchers to target the right biological processes at the right time. The future of IPF management lies in moving upstream, utilizing the sentinel signal of DLCO decline to intervene before the 12-fold acceleration of FVC loss leads to irreversible respiratory failure.
References
- Huang X, Wu P, Guttentag AR, Quintana M, Kropski JA, Blackwell TS, Salisbury ML. Identification of a conserved sequence of disease progression in Idiopathic Pulmonary Fibrosis. American journal of respiratory and critical care medicine. 2026;213(4):450-462. PMID: 41738263.
- Ley B, et al. A clinical predictive model for outcomes in idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. PMID: 22586007.
- Martinez FJ, et al. The clinical course of idiopathic pulmonary fibrosis. Chest. 2005;128(1 Suppl):27S-33S. PMID: 15994468.
